Sanofi
SNYNFDrugs in Pipeline
168
Phase 3 Programs
105
Upcoming Catalysts
3
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
SSR591813L (dianicline)
Smoking Cessation
DTaP-IPV-HB-PRP~T vaccine
Diphtheria
Dermacyd PH_DETINBACK (Lactic Acid)
Hygiene
Isatuximab SAR650984
Plasma Cell Myeloma
Semuloparin sodium
Venous Thromboembolism
Lactic acid (Dermacid)
Hygiene
Dermacyd Femina Pocket BR (Lactic Acid)
Hygiene
Ramipril
Glomerulonephritis
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)
Meningococcal Immunisation (Healthy Volunteers)
HOE901-U300 (new formulation of insulin glargine)
Type 2 Diabetes Mellitus
hydroxychloroquine
Rheumatoid Arthritis
Teriflunomide
Multiple Sclerosis
Cetylpyridinium chloride
Healthy
SR34006 (idraparinux sodium) Injection
Atrial Fibrillation
Lipid-Modifying Therapy (LMT)
Hypercholesterolemia
Lunsekimig
Chronic Obstructive Pulmonary Disease
telithromycin (HMR3647)
Infections
Vandetanib
Thyroid Neoplasms
Lactic Acid
Hygiene
Sarilumab SAR153191
Corona Virus Infection
Sevelamer carbonate (Renvela®)
Chronic Kidney Disease
Telithromycin
Asthma
Insulin glargine U100 (HOE901)
Type 2 Diabetes Mellitus
Granulocyte colony-stimulating factor plus plerixafor
Multiple Myeloma
Docetaxel (TAXOTERE®) Chemotherapy
Prostatic Neoplasms
Fitusiran
Hemophilia
Insulin glargine (HOE901)
Type 2 Diabetes
Itepekimab (SAR440340)
Chronic Rhinosinusitis With Nasal Polyps
insulin lispro
Diabetes Mellitus, Insulin-Dependent
Saredutant
Depressive Disorder
rilzabrutinib
Immune Thrombocytopenia
Tolebrutinib
Relapsing Multiple Sclerosis
Insulin glulisine
Diabetes Mellitus, Type 1
Rimonabant
Diabetes Mellitus, Type 2
sarilumab SAR153191 (REGN88)
Rheumatoid Arthritis
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Infection (Healthy Volunteers)
Dupilumab SAR231893 (REGN668)
Asthma
Saredutant succinate (SR48968C)
Depressive Disorder
Alemtuzumab
Multiple Sclerosis, Relapsing-Remitting
5-FLUOROURACIL
Head and Neck Neoplasms
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Neoplasms
Duvakitug
Crohn's Disease
Xaliproden (SR57746A)
Metastases
SR48692
Lung Cancer
efanesoctocog alfa (BIVV001)
Factor VIII Deficiency
gemcitabine/carboplatin
Breast Cancer
ZD6474 (vandetanib)
Non-Small-Cell Lung Carcinoma
Cabazitaxel (XRP6258)
Prostate Cancer
Enoxaparin sodium (XRP4563)
Myocardial Infarction
Artesunate + Amodiaquine
Malaria
Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Hygiene
fexofenadine/Allegra (M016455)
Rhinitis Perennial
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Healthy Volunteers (Meningococcal Infection)
MenACYW conjugate vaccine
Meningococcal Immunisation
Lipid Modifying Therapy (LMT)
Hypercholesterolaemia
tolevamer potassium-sodium (GT267-004)
Pseudomembranous Colitis
Aflibercept
Colorectal Cancer Metastatic
Iniparib
Breast Cancer, Metastatic
Influenza virus vaccine (split virion, inactivated)
Influenza
ALIROCUMAB SAR236553 (REGN727)
Hypercholesterolemia
dronedarone (SR33589)
Atrial Fibrillation
Amlitelimab
Asthma
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Type 2 Diabetes Mellitus
PCV21
Sickle Cell Disease
Teriflunomide (HMR1726)
Multiple Sclerosis
Insulin glargine/lixisenatide Fixed Ratio Combination
Type 2 Diabetes
Irbesartan
Atrial Fibrillation
teriflunomide HMR1726
Multiple Sclerosis
Mitoxantrone
Prostatic Neoplasms
rhIDU (recombinant human-Alpha-L-Iduronidase)
Mucopolysaccharidosis I
escitalopram
Major Depressive Disorder
SR121463B
Inappropriate ADH Syndrome
Olipudase alfa
Sphingomyelin Lipidosis
Myozyme
Glycogen Storage Disease Type II
Itepekimab SAR440340
Chronic Obstructive Pulmonary Disease
Insulin glulisine QD
Type 2 Diabetes
Enoxaparin sodium
Percutaneous Coronary Intervention
Ciclesonide (XRP1526)
Asthma
Yellow fever vaccine (live)
Yellow Fever
Dermacyd PH_DETINLYN (Lactic Acid)
Hygiene
Lixisenatide (AVE0010)
Type 2 Diabetes Mellitus
LACTIC ACID(ND)
Hygiene
Insuline glulisine
Diabetes Mellitus, Type 1
Rimonabant (SR141716)
Obesity
amibegron (SR58611A)
Major Depressive Disorders
Alfuzosin
Prostatic Hyperplasia
Eliglustat tartrate
Gaucher Disease, Type 1
SR58611A
Depressive Disorder
Larotaxel (XRP9881)
Pancreatic Neoplasms
lactoserum
Hygiene
NVX-CoV2705
COVID-19
Lispro
Diabetes Mellitus
cabazitaxel (XRP6258) (RPR116258)
Neoplasms
Thyrogen + Radioiodine (131I)
Thyroid Neoplasms
alfuzosin (SL770499)
Urinary Bladder Neurogenic
Alirocumab
Hypercholesterolemia
Caplacizumab
Acquired Thrombotic Thrombocytopenic Purpura
Fexofenadine
Asthma
Dupilumab
Chronic Spontaneous Urticaria
Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Diphtheria
leflunomide
Arthritis, Rheumatoid
Sarilumab
Rheumatoid Arthritis
Dupilumab SAR231893
Chronic Rhinosinusitis Without Nasal Polyps
INSULIN GLARGINE (U300)
Type 2 Diabetes Mellitus
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Healthy Volunteers (Meningococcal Infection)
SAR3419
Diffuse Large B-cell Lymphoma
XRP0038 (NV1FGF)
Peripheral Arterial Occlusive Disease
Inactivated, Split-Virion Influenza Virus
Influenza
clofarabine (IV formulation)
Acute Myelogenous Leukemia
Split, Inactivated, Trivalent Influenza Vaccine
Orthomyxoviridae Infection
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
Systemic Sclerosis
Levofolinate
Colorectal Cancer Metastatic
Swine A/H1N1 influenza vaccine (split virion, inactivated)
Influenza
ataciguat (HMR1766)
Pain
Oxaliplatin (SR96669)
Gastrointestinal Cancer
Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
Cadaveric Donor Renal Transplantation
RISEDRONATE
OSTEOPOROSIS, POSTMENOPAUSAL
venglustat (GZ402671)
Gaucher Disease Type 1
ILX651
Hormone-refractory Prostate Cancer
Avalglucosidase Alfa
Glycogen Storage Disease Type II Pompe Disease
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
Meningitis
G-CSF Plus Plerixafor
Lymphoma, Non-Hodgkin
frexalimab
Focal Segmental Glomerulosclerosis
XL147 (SAR245408)
Breast Cancer
SAR443122
Cutaneous Lupus Erythematosus
Alglucosidase alfa
Glycogen Storage Disease Type II
Isatuximab
Relapsed/Refractory Multiple Myeloma
Acne mRNA vaccine
Acne
SAR245409
Lymphoma
Doxercalciferol
Moderate to Severe Chronic Plaque Psoriasis
RSVt Vaccine
Respiratory Syncytial Virus Infection
SSR149415
Anxiety Disorders
cabazitaxel XRP6258
Gastric Cancer
ZD6474, Vandetanib
Biliary Tract Cancer
SAR156597
Systemic Sclerosis
SR57667B
Parkinson Disease
Inactivated, split-virion influenza vaccine
Influenza
eplivanserin (SR46349)
Fibromyalgia
ombrabulin (AVE8062)
Non-small Cell Lung Cancer
Ad2/HIF-1α/VP16
Intermittent Claudication
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
Influenza
Belumosudil
Chronic Graft Versus Host Disease
Fabrazyme (agalsidase beta)
Fabry Disease
GZ/SAR402671
Fabry Disease
satavaptan (SR121463B)
Ascites
SAR441566
Psoriasis
Mometasone furoate nasal spray
Nasal Polyps
Influenza Virus Vaccine USP Trivalent Types A and B
Influenza
rasburicase (SR29142)
Nutritional and Metabolic Diseases
plerixafor GZ316455
Lymphoma
DOCETAXEL XRP6976
Squamous Cell Carcinoma of Head and Neck
Oxaliplatin, 5-FU
Head and Neck Cancer
Sevelamer carbonate
Hyperphosphatemia
Fludarabine Phosphate (Fludara)
Non Hodgkin Lymphoma
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Mucopolysaccharidosis I
Nerispirdine
Multiple Sclerosis
ATN-103
Active Rheumatoid Arthritis
CYD Dengue Vaccine
Dengue
ZD6474
Breast Neoplasms
clofarabine
Acute Myelogenous Leukemia
Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
Lung Neoplasms
A/H5N1 inactivated, split-virion influenza virus
Influenza
SAR442970
Ulcerative Colitis
Teplizumab
Type 1 Diabetes Mellitus
plerixafor
Ewing's Sarcoma/Soft Tissue Sarcoma
ALX-0061
Rheumatoid Arthritis
docetaxel (XRP6976)
Therapy, Prostatic Neoplasms
BSI-201
Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SSR591813L (dianicline) | Phase 3 | Smoking Cessation | - | - |
DTaP-IPV-HB-PRP~T vaccine | Phase 3 | Diphtheria | - | - |
Dermacyd PH_DETINBACK (Lactic Acid) | Phase 3 | Hygiene | - | - |
Isatuximab SAR650984 | Phase 3 | Plasma Cell Myeloma | - | - |
Semuloparin sodium | Phase 3 | Venous Thromboembolism | - | - |
Lactic acid (Dermacid) | Phase 3 | Hygiene | - | - |
Dermacyd Femina Pocket BR (Lactic Acid) | Phase 3 | Hygiene | - | - |
Ramipril | Phase 3 | Glomerulonephritis | - | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine) | Phase 3 | Meningococcal Immunisation (Healthy Volunteers) | - | - |
HOE901-U300 (new formulation of insulin glargine) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
hydroxychloroquine | Phase 3 | Rheumatoid Arthritis | - | - |
Teriflunomide | Phase 3 | Multiple Sclerosis | - | - |
Cetylpyridinium chloride | Phase 3 | Healthy | - | - |
SR34006 (idraparinux sodium) Injection | Phase 3 | Atrial Fibrillation | - | - |
Lipid-Modifying Therapy (LMT) | Phase 3 | Hypercholesterolemia | - | - |
Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
telithromycin (HMR3647) | Phase 3 | Infections | - | - |
Vandetanib | Phase 3 | Thyroid Neoplasms | - | - |
Lactic Acid | Phase 3 | Hygiene | - | - |
Sarilumab SAR153191 | Phase 3 | Corona Virus Infection | - | - |
Sevelamer carbonate (Renvela®) | Phase 3 | Chronic Kidney Disease | - | - |
Telithromycin | Phase 3 | Asthma | - | - |
Insulin glargine U100 (HOE901) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Granulocyte colony-stimulating factor plus plerixafor | Phase 3 | Multiple Myeloma | - | - |
Docetaxel (TAXOTERE®) Chemotherapy | Phase 3 | Prostatic Neoplasms | - | - |
Fitusiran | Phase 3 | Hemophilia | - | - |
Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes | - | - |
Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | - | - |
insulin lispro | Phase 3 | Diabetes Mellitus, Insulin-Dependent | - | - |
Saredutant | Phase 3 | Depressive Disorder | - | - |
rilzabrutinib | Phase 3 | Immune Thrombocytopenia | - | - |
Tolebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Insulin glulisine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Rimonabant | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
sarilumab SAR153191 (REGN88) | Phase 3 | Rheumatoid Arthritis | - | - |
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | Phase 3 | Meningococcal Infection (Healthy Volunteers) | - | - |
Dupilumab SAR231893 (REGN668) | Phase 3 | Asthma | - | - |
Saredutant succinate (SR48968C) | Phase 3 | Depressive Disorder | - | - |
Alemtuzumab | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
5-FLUOROURACIL | Phase 3 | Head and Neck Neoplasms | - | - |
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Phase 3 | Neoplasms | - | - |
Duvakitug | Phase 3 | Crohn's Disease | - | - |
Xaliproden (SR57746A) | Phase 3 | Metastases | - | - |
SR48692 | Phase 3 | Lung Cancer | - | - |
efanesoctocog alfa (BIVV001) | Phase 3 | Factor VIII Deficiency | - | - |
gemcitabine/carboplatin | Phase 3 | Breast Cancer | - | - |
ZD6474 (vandetanib) | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
Cabazitaxel (XRP6258) | Phase 3 | Prostate Cancer | - | - |
Enoxaparin sodium (XRP4563) | Phase 3 | Myocardial Infarction | - | - |
Artesunate + Amodiaquine | Phase 3 | Malaria | - | - |
Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix) | Phase 3 | Hygiene | - | - |
fexofenadine/Allegra (M016455) | Phase 3 | Rhinitis Perennial | - | - |
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine | Phase 3 | Healthy Volunteers (Meningococcal Infection) | - | - |
MenACYW conjugate vaccine | Phase 3 | Meningococcal Immunisation | - | - |
Lipid Modifying Therapy (LMT) | Phase 3 | Hypercholesterolaemia | - | - |
tolevamer potassium-sodium (GT267-004) | Phase 3 | Pseudomembranous Colitis | - | - |
Aflibercept | Phase 3 | Colorectal Cancer Metastatic | - | - |
Iniparib | Phase 3 | Breast Cancer, Metastatic | - | - |
Influenza virus vaccine (split virion, inactivated) | Phase 3 | Influenza | - | - |
ALIROCUMAB SAR236553 (REGN727) | Phase 3 | Hypercholesterolemia | - | - |
dronedarone (SR33589) | Phase 3 | Atrial Fibrillation | - | - |
Amlitelimab | Phase 3 | Asthma | - | - |
Insulin glargine/Lixisenatide (HOE901/AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
PCV21 | Phase 3 | Sickle Cell Disease | - | - |
Teriflunomide (HMR1726) | Phase 3 | Multiple Sclerosis | - | - |
Insulin glargine/lixisenatide Fixed Ratio Combination | Phase 3 | Type 2 Diabetes | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
teriflunomide HMR1726 | Phase 3 | Multiple Sclerosis | - | - |
Mitoxantrone | Phase 3 | Prostatic Neoplasms | - | - |
rhIDU (recombinant human-Alpha-L-Iduronidase) | Phase 3 | Mucopolysaccharidosis I | - | - |
escitalopram | Phase 3 | Major Depressive Disorder | - | - |
SR121463B | Phase 3 | Inappropriate ADH Syndrome | - | - |
Olipudase alfa | Phase 3 | Sphingomyelin Lipidosis | - | - |
Myozyme | Phase 3 | Glycogen Storage Disease Type II | - | - |
Itepekimab SAR440340 | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Insulin glulisine QD | Phase 3 | Type 2 Diabetes | - | - |
Enoxaparin sodium | Phase 3 | Percutaneous Coronary Intervention | - | - |
Ciclesonide (XRP1526) | Phase 3 | Asthma | - | - |
Yellow fever vaccine (live) | Phase 3 | Yellow Fever | - | - |
Dermacyd PH_DETINLYN (Lactic Acid) | Phase 3 | Hygiene | - | - |
Lixisenatide (AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LACTIC ACID(ND) | Phase 3 | Hygiene | - | - |
Insuline glulisine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Rimonabant (SR141716) | Phase 3 | Obesity | - | - |
amibegron (SR58611A) | Phase 3 | Major Depressive Disorders | - | - |
Alfuzosin | Phase 3 | Prostatic Hyperplasia | - | - |
Eliglustat tartrate | Phase 3 | Gaucher Disease, Type 1 | - | - |
SR58611A | Phase 3 | Depressive Disorder | - | - |
Larotaxel (XRP9881) | Phase 3 | Pancreatic Neoplasms | - | - |
lactoserum | Phase 3 | Hygiene | - | - |
NVX-CoV2705 | Phase 3 | COVID-19 | - | - |
Lispro | Phase 3 | Diabetes Mellitus | - | - |
cabazitaxel (XRP6258) (RPR116258) | Phase 3 | Neoplasms | - | - |
Thyrogen + Radioiodine (131I) | Phase 3 | Thyroid Neoplasms | - | - |
alfuzosin (SL770499) | Phase 3 | Urinary Bladder Neurogenic | - | - |
Alirocumab | Phase 3 | Hypercholesterolemia | - | - |
Caplacizumab | Phase 3 | Acquired Thrombotic Thrombocytopenic Purpura | - | - |
Fexofenadine | Phase 3 | Asthma | - | - |
Dupilumab | Phase 3 | Chronic Spontaneous Urticaria | - | - |
Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib | Phase 3 | Diphtheria | - | - |
leflunomide | Phase 3 | Arthritis, Rheumatoid | - | - |
Sarilumab | Phase 3 | Rheumatoid Arthritis | - | - |
Dupilumab SAR231893 | Phase 3 | Chronic Rhinosinusitis Without Nasal Polyps | - | - |
INSULIN GLARGINE (U300) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine | Phase 3 | Healthy Volunteers (Meningococcal Infection) | - | - |
SAR3419 | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
XRP0038 (NV1FGF) | Phase 2 | Peripheral Arterial Occlusive Disease | - | - |
Inactivated, Split-Virion Influenza Virus | Phase 2 | Influenza | - | - |
clofarabine (IV formulation) | Phase 2 | Acute Myelogenous Leukemia | - | - |
Split, Inactivated, Trivalent Influenza Vaccine | Phase 2 | Orthomyxoviridae Infection | - | - |
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | Phase 2 | Systemic Sclerosis | - | - |
Levofolinate | Phase 2 | Colorectal Cancer Metastatic | - | - |
Swine A/H1N1 influenza vaccine (split virion, inactivated) | Phase 2 | Influenza | - | - |
ataciguat (HMR1766) | Phase 2 | Pain | - | - |
Oxaliplatin (SR96669) | Phase 2 | Gastrointestinal Cancer | - | - |
Thymoglobulin [Anti-thymocyte Globulin (rabbit)] | Phase 2 | Cadaveric Donor Renal Transplantation | - | - |
RISEDRONATE | Phase 2 | OSTEOPOROSIS, POSTMENOPAUSAL | - | - |
venglustat (GZ402671) | Phase 2 | Gaucher Disease Type 1 | - | - |
ILX651 | Phase 2 | Hormone-refractory Prostate Cancer | - | - |
Avalglucosidase Alfa | Phase 2 | Glycogen Storage Disease Type II Pompe Disease | - | - |
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine | Phase 2 | Meningitis | - | - |
G-CSF Plus Plerixafor | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
frexalimab | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
XL147 (SAR245408) | Phase 2 | Breast Cancer | - | - |
SAR443122 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
Alglucosidase alfa | Phase 2 | Glycogen Storage Disease Type II | - | - |
Isatuximab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Acne mRNA vaccine | Phase 2 | Acne | - | - |
SAR245409 | Phase 2 | Lymphoma | - | - |
Doxercalciferol | Phase 2 | Moderate to Severe Chronic Plaque Psoriasis | - | - |
RSVt Vaccine | Phase 2 | Respiratory Syncytial Virus Infection | - | - |
SSR149415 | Phase 2 | Anxiety Disorders | - | - |
cabazitaxel XRP6258 | Phase 2 | Gastric Cancer | - | - |
ZD6474, Vandetanib | Phase 2 | Biliary Tract Cancer | - | - |
SAR156597 | Phase 2 | Systemic Sclerosis | - | - |
SR57667B | Phase 2 | Parkinson Disease | - | - |
Inactivated, split-virion influenza vaccine | Phase 2 | Influenza | - | - |
eplivanserin (SR46349) | Phase 2 | Fibromyalgia | - | - |
ombrabulin (AVE8062) | Phase 2 | Non-small Cell Lung Cancer | - | - |
Ad2/HIF-1α/VP16 | Phase 2 | Intermittent Claudication | - | - |
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant | Phase 2 | Influenza | - | - |
Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | - | - |
Fabrazyme (agalsidase beta) | Phase 2 | Fabry Disease | - | - |
GZ/SAR402671 | Phase 2 | Fabry Disease | - | - |
satavaptan (SR121463B) | Phase 2 | Ascites | - | - |
SAR441566 | Phase 2 | Psoriasis | - | - |
Mometasone furoate nasal spray | Phase 2 | Nasal Polyps | - | - |
Influenza Virus Vaccine USP Trivalent Types A and B | Phase 2 | Influenza | - | - |
rasburicase (SR29142) | Phase 2 | Nutritional and Metabolic Diseases | - | - |
plerixafor GZ316455 | Phase 2 | Lymphoma | - | - |
DOCETAXEL XRP6976 | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
Oxaliplatin, 5-FU | Phase 2 | Head and Neck Cancer | - | - |
Sevelamer carbonate | Phase 2 | Hyperphosphatemia | - | - |
Fludarabine Phosphate (Fludara) | Phase 2 | Non Hodgkin Lymphoma | - | - |
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | Phase 2 | Mucopolysaccharidosis I | - | - |
Nerispirdine | Phase 2 | Multiple Sclerosis | - | - |
ATN-103 | Phase 2 | Active Rheumatoid Arthritis | - | - |
CYD Dengue Vaccine | Phase 2 | Dengue | - | - |
ZD6474 | Phase 2 | Breast Neoplasms | - | - |
clofarabine | Phase 2 | Acute Myelogenous Leukemia | - | - |
Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine | Phase 2 | Lung Neoplasms | - | - |
A/H5N1 inactivated, split-virion influenza virus | Phase 2 | Influenza | - | - |
SAR442970 | Phase 2 | Ulcerative Colitis | - | - |
Teplizumab | Phase 2 | Type 1 Diabetes Mellitus | - | - |
plerixafor | Phase 2 | Ewing's Sarcoma/Soft Tissue Sarcoma | - | - |
ALX-0061 | Phase 2 | Rheumatoid Arthritis | - | - |
docetaxel (XRP6976) | Phase 2 | Therapy, Prostatic Neoplasms | - | - |
BSI-201 | Phase 2 | Ovarian Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sanofi's drug pipeline?→
CatalystAlert tracks 168 drug candidates in Sanofi's (SNYNF) pipeline across Phase 3, Phase 2. Its lead program is SSR591813L (dianicline) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sanofi's next FDA catalyst?→
Sanofi's (SNYNF) next tracked catalyst is a Phase 2 expected October 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SNYNF biotech catalysts?→
Add SNYNF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sanofi's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.